Cancer Therapy Is Changing Diabetes Management: What Clinicians Need to Know Now

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose instability, even without a prior diabetes diagnosis.

The 2026 ADA Standards of Care place greater attention on diabetes management during cancer treatment, particularly for patients receiving modern immunotherapies and targeted therapies. Clinicians are being encouraged to recognize treatment-related hyperglycemia earlier, monitor glucose patterns more closely, and intervene before severe metabolic complications develop.

For endocrinologists, oncologists, and primary care providers, the overlap between cancer therapy and glucose management is becoming impossible to ignore.

Table of Contents

• How cancer therapies affect glucose control
• New ADA guidance for immune checkpoint inhibitors
• PI3K inhibitors and treatment-related hyperglycemia
• Why metformin and CGM are gaining importance
• Frequently asked questions

How Cancer Therapies Affect Glucose Control

Modern cancer therapies work differently from traditional chemotherapy. Instead of simply destroying rapidly dividing cells, many newer treatments target immune pathways or molecular signaling systems. While these approaches improve cancer outcomes, they can also disrupt metabolic balance.

Immune checkpoint inhibitors, including PD-1, PD-L1, and CTLA-4 inhibitors, activate the immune system to attack cancer cells. However, that immune activation may also damage pancreatic beta cells. In some cases, patients develop abrupt insulin deficiency resembling type 1 diabetes. Hyperglycemia can appear suddenly and may progress to diabetic ketoacidosis (DKA).

PI3K inhibitors create a different challenge. These targeted therapies interfere with insulin signaling pathways that are essential for glucose regulation. As a result, insulin resistance can rise sharply during treatment. Some patients experience severe glucose elevations within days or weeks of starting therapy.

According to the updated ADA Standards of Care, clinicians should now anticipate glucose abnormalities in patients receiving these therapies rather than treating them as rare complications.

This shift reflects a growing understanding that glucose management in oncology patients requires proactive planning rather than reactive care.

ADA Updates on Immune Checkpoint Inhibitors

The 2026 ADA guidance emphasizes early recognition and routine monitoring for patients treated with ICIs. Although immune-mediated diabetes remains relatively uncommon, the consequences can be serious if missed.

Patients receiving checkpoint inhibitors may present with rapid-onset hyperglycemia, polyuria, polydipsia, unexplained weight loss, ketosis, or DKA. Unlike traditional type 2 diabetes, ICI-induced diabetes often develops abruptly. Many patients require insulin therapy immediately after diagnosis.

The ADA now recommends baseline glucose assessment before initiating immunotherapy and ongoing monitoring throughout treatment. Clinicians are also encouraged to educate patients about symptoms of severe hyperglycemia because progression can occur quickly.

Importantly, multidisciplinary coordination is becoming a major component of caring for patients with both cancer and diabetes. Oncologists, endocrinologists, diabetes educators, and primary care teams must work together to reduce delays in diagnosis and treatment.

This collaborative approach may improve patient safety while allowing cancer therapy to continue whenever possible.

PI3K Inhibitors and Treatment-Related Hyperglycemia

PI3K inhibitors are increasingly used for certain breast cancers and other malignancies. However, they are strongly associated with hyperglycemia because they directly impair insulin signaling.

Clinical studies have shown that glucose elevations can occur in a large percentage of patients receiving these therapies. In some individuals, hyperglycemia becomes severe enough to interrupt cancer treatment.

The ADA’s updated recommendations highlight the importance of frequent glucose monitoring during the first weeks of therapy. Patients with preexisting diabetes, obesity, or metabolic syndrome may face even higher risks.

One notable change in the evolving field of oncology-related diabetes management is the growing use of metformin as a preferred first-line therapy for PI3K inhibitor-related hyperglycemia.

Metformin offers several advantages. It improves insulin sensitivity, has a long-established safety profile, carries a low risk of hypoglycemia, and may support continuation of cancer therapy.

Clinicians are increasingly initiating metformin early when glucose levels begin to rise during treatment. Additional therapies may still be necessary, especially in patients with severe insulin resistance. However, metformin often provides an effective starting point for managing treatment-associated glucose elevations.

Patients who cannot tolerate metformin or who develop significant hyperglycemia may require insulin or other glucose-lowering therapies. Care plans should always be individualized based on cancer status, nutritional intake, renal function, and treatment goals.

CGM Is Becoming More Valuable During Cancer Treatment

Continuous glucose monitoring is gaining attention as an important tool for managing blood glucose during cancer treatment. Traditional fingerstick testing may miss rapid fluctuations in glucose levels, particularly in patients receiving steroids, immunotherapy, or targeted agents.

CGM offers several potential benefits during active cancer treatment. It may help clinicians detect severe hyperglycemia earlier, identify glucose variability, reduce the burden of repeated fingersticks, and recognize nocturnal hypoglycemia sooner.

For patients undergoing intensive cancer treatment, glucose patterns may change rapidly from day to day. CGM provides clinicians with a more complete picture of glycemic trends.

The ADA notes that CGM may support safer glucose management in high-risk oncology patients, especially those receiving insulin therapy or therapies known to cause metabolic disturbances.

There is also increasing interest in whether CGM data can help clinicians avoid unnecessary treatment interruptions. By identifying glucose changes earlier, providers may be able to stabilize patients while maintaining cancer therapy schedules.

As technology becomes more accessible, CGM could become a routine component of diabetes management in both inpatient and outpatient oncology settings.

Clinicians should also consider the emotional burden many patients face during simultaneous cancer and diabetes management. Simplifying glucose monitoring may reduce treatment fatigue and improve adherence during an already stressful period.

Patients seeking guidance on diabetes management during cancer treatment can also connect with healthcare professionals through Healthcare.pro for additional support and care resources.

Conclusion

Cancer therapy is reshaping how clinicians approach glucose management. Immune checkpoint inhibitors and PI3K inhibitors are increasing the frequency of treatment-related hyperglycemia, creating new challenges across oncology and endocrinology.

The 2026 ADA Standards of Care recognize the growing importance of diabetes management during cancer therapy by emphasizing early monitoring, multidisciplinary collaboration, and individualized treatment strategies. Metformin is emerging as a practical first-line option for many patients experiencing PI3K inhibitor-associated hyperglycemia, while CGM is becoming an increasingly valuable tool for improving patient safety during active cancer treatment.

As cancer therapies continue to evolve, clinicians must remain prepared to recognize and manage the metabolic complications that often accompany these advances.

FAQs

What is diabetes oncology care?

Diabetes oncology care focuses on managing glucose disorders in patients undergoing cancer treatment. It often involves collaboration between oncologists, endocrinologists, and diabetes specialists.

Why do immune checkpoint inhibitors cause diabetes?

Immune checkpoint inhibitors can trigger immune-mediated destruction of pancreatic beta cells, leading to sudden insulin deficiency and severe hyperglycemia.

Are PI3K inhibitors linked to hyperglycemia?

Yes. PI3K inhibitors interfere with insulin signaling pathways, which can significantly increase blood glucose levels during treatment.

Why is metformin commonly used in these patients?

Metformin improves insulin sensitivity and has a favorable safety profile, making it a commonly recommended first-line option for therapy-related hyperglycemia.

How can CGM help during cancer treatment?

Continuous glucose monitoring helps detect rapid glucose changes, improve glycemic monitoring, and support safer diabetes management during active cancer therapy.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.